A global scoping review of 74 primary studies found that vaccination programs measurably reduce antibiotic consumption and drug-resistant infections. By positioning immunization as upstream antimicrobial stewardship, the analysis ties prevention to downstream antimicrobial use outcomes. The review links reductions in antibiotic use with fewer resistant infections, reinforcing the idea that vaccines can lower selective pressure driving antimicrobial resistance. The evidence base spans multiple settings and vaccine types, aggregated through the scoping approach. For biotech and pharma stakeholders, the practical takeaway is that vaccine value propositions increasingly include stewardship and resistance outcomes—not only disease incidence. This may influence health-technology assessments and payer decisions. The review also highlights an evidence need for more standardized measurement of antibiotic impacts across studies, as well as longer follow-up to capture resistance dynamics. Overall, the work supports vaccine portfolio strategy as a lever in combating antimicrobial resistance while cutting healthcare costs associated with resistant infections.